The “urgency” imposed by the pandemic makes “for the first time in history” phases I, II and III are carried out “in parallel” of clinical research when developing a vaccine. This was stated by Antonio Fernández, director of market access and government relations at Janssen Spain, when it was learned that Health had authorized the first clinical trial of an antidote against the coronavirus in the country. And so it is.
The Belgian pharmaceutical company began the second phase of its study with the preliminary safety data obtained from I and has in turn overlapped it with III, which has already started. This has been confirmed by the US National Institute of Allergies and Infectious Diseases (NIAID), which points out that they have begun to recruit volunteers. A total of 60,000 will be needed for a study to be carried out in some 215 clinical research organizations, both in the US and abroad. “The trial is aimed at evaluating whether the vaccine can prevent infection after a single dose,” explains the institute.
“Four candidates have reached phase III in the US in less than eight months. This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated strategic approach between government, industry and academia, “said NIAID Director Anthony S. . Fauci. “It is likely that multiple types of vaccine will be required to meet the global need. Janssen’s candidate has shown promise in initial testing and may be especially helpful in controlling the pandemic if it is shown to protect after just one dose, “he added.
While that happens on the other side of the Atlantic, phase II continues in the hospitals of La Princesa and La Paz, both in Madrid, and the Marqués de Valdecilla, in Santander. This Wednesday precisely the journalists have asked about the matter the Minister of Health of Cantabria, Miguel Rodríguez, who has responded that for now “everything is correct” and “with absolute normality.
The 190 volunteers selected they began to receive the first injection on September 14.